Targeting interleukin-6 trans-signaling in head and neck squamous cell carcinoma

2018 ◽  
Author(s):  
Rachel A. Dahl
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Interleukin 6 ◽  
Neck Squamous Cell Carcinoma

Regulation of Interleukin-6 in Head and Neck Squamous Cell Carcinoma Is Related to Papillomavirus Infection

2014 ◽  
Vol 13 (2) ◽  
pp. 1002-1011 ◽  
Author(s):  
Ida Chiara Guerrera ◽  
Ivan Quetier ◽  
Rachid Fetouchi ◽  
Frederique Moreau ◽  
Christelle Vauloup-Fellous ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Interleukin 6 ◽  
Neck Squamous Cell Carcinoma ◽  
Papillomavirus Infection

scholarly journals Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma

2015 ◽  
Vol 9 (7) ◽  
pp. 1371-1383 ◽  
Author(s):  
Aditya Stanam ◽  
Laurie Love-Homan ◽  
Tisha S. Joseph ◽  
Madelyn Espinosa-Cotton ◽  
Andrean L. Simons
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Interleukin 6 ◽  
Neck Squamous Cell Carcinoma

scholarly journals Association Between Interleukin-6 and Head and Neck Squamous Cell Carcinoma: A Systematic Review

2021 ◽  
Vol 14 (1) ◽  
pp. 50-60
Author(s):  
Uzdan Uz ◽  
Görkem Eskiizmir
Keyword(s):  
Systematic Review ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Targeted Therapies ◽  
Interleukin 6 ◽  
Randomized Clinical Trials ◽  
Elevated Serum ◽  
Neck Squamous Cell Carcinoma

Interleukin-6 (IL-6) is a proinflammatory cytokine which plays an important role in several regulatory mechanisms of cancer. Moreover, experimental and clinical studies have reported that IL-6 targeted therapies might provide significant benefits for cancer treatment. The purpose of this systematic review is to evaluate IL-6 activity in patients with head and neck squamous cell carcinoma (HNSCC). A systematic review of the association between serum, saliva and tumor IL-6 and HNSCC was developed on PubMed/Medline in the publication range from January 1995 to January 2019. Our literature analysis demonstrated that overexpression and elevated serum and/or saliva IL-6 concentrations in patients with HNSCC are related to poor survival and oncological outcomes. Although there is a correlation between IL-6 concentrations and tumorigenicity, it is noteworthy that IL-6 targeted therapies are generally performed in vitro and in experimental studies. Therefore, prospective, randomized clinical trials are required that focus on IL-6 targeted therapies for the treatment of HNSCC.

Sign in / Sign up

Export Citation Format

Share Document